Kardium Inc., the Vancouver, BC, Canada-based developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, raised US $104m in new financing.
The round was led by existing investor Fidelity Management & Research Company, together with follow-on participation by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc. as well as new investor Durable Capital Partners LP.
The company intends to use the funds to complete its PULSAR clinical study in order to obtain regulatory approvals for the Globe System, to grow the manufacturing team and capacity, and to build a clinical support and commercial team in preparation for the commercial launch of the Globe System.
Founded in 2007 and led by Kevin Chaplin, CEO, Kardium has developed the Globe Mapping and Ablation System, which consists of a sophisticated catheter with a 122-electrode array and advanced software that enable rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium – all with a single catheter.
FinSMEs
12/06/2024